Selected Articles from This Issue
- PMID: 34853073
- DOI: 10.1158/1078-0432.CCR-27-23-HI
Selected Articles from This Issue
Comment in
-
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial.Clin Cancer Res. 2021 Dec 1;27(23):6500-6513. doi: 10.1158/1078-0432.CCR-21-1652. Epub 2021 Sep 8. Clin Cancer Res. 2021. PMID: 34497073 Free PMC article.
-
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526366 Free PMC article.
-
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.Clin Cancer Res. 2021 Dec 1;27(23):6384-6392. doi: 10.1158/1078-0432.CCR-21-2031. Epub 2021 Sep 21. Clin Cancer Res. 2021. PMID: 34548316 Free PMC article.
-
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.Clin Cancer Res. 2021 Dec 1;27(23):6314-6322. doi: 10.1158/1078-0432.CCR-21-1789. Epub 2021 Sep 27. Clin Cancer Res. 2021. PMID: 34580114 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources